Last reviewed · How we verify
NCT04942340
Turning Dexmedetomidine Into a Powerful Anesthetic That Can be Rapidly and Completely Reversed
Phase 1 trial testing Atipamezole & Caffeine in Emergence From Anesthesia. Withdrawn.
1 April 2026
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 1 May 2023 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Atipamezole & Caffeine — full drug profile →
- Dexmedetomidine Hydrochloride & Saline — full drug profile →
Conditions studied
- Emergence From Anesthesia — all drugs for Emergence From Anesthesia →
Sponsor
University of Chicago
Who can join
Adults 22 to 39, any sex, with Emergence From Anesthesia. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The time when the drug injections are complete to the awakening of the subject.
Time frame: 1 Day
We will record the time until the subject's eyes open, and the time until the subject can respond to the command to grip the hand of the attending physician
Sponsor's own description
In this study, the investigators will explore Atipamezole \& caffeine's ability to facilitate the emergence from anesthesia. Each subject will visit UChicago 4 times. The first time for informed consent. The second time for a complete physical exam to ensure that the subjects are healthy. Then there are 2 sedation sessions. Subjects get an honorarium for each sedation session.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04942340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Emergence From Anesthesia
Currently open trials in the same condition.
- NCT07435675 — Efficacy of Ultrasound-guided Greater Auricular Nerve Block in Preventing Postoperative Emergence Agitation in Pediatric · NA · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04942340 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 15 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04942340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing